Titian Pharma regains rights from Braebrun Pharma to Probuphine which is approved in the US and Canada for maintenance treatment of opioid dependence.
Titan Pharmaceuticals, Inc. and Braeburn announce that they have agreed to terminate the December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the United States and Canada. Under the terms of the termination agreement, Titan will regain all rights to the commercialization and clinical development of Probuphine in the U.S. and Canada.
Braeburn has paid Titan $1 million and will provide assistance to Titan through December 28, 2018, to enable a smooth transition and ensure that patients and their doctors will continue to have support and access to this treatment. In addition, the parties will immediately transfer to Titan all regulatory documentation and development data related to Probuphine.
Comment: Probuphine was approved in the US on 26 May 2016 for for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine containing product. The licensee of the Canadian rights is Knight Therapeutics and the drug was approved in Canada in April 2018. /p>
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins